Molecular mechanisms of growth factor action in diabetic retinopathy

Current Opinion in Endocrinology and Diabetes

Volumn 6, Issue 2, 1999, Pages 146-156

  Aiello, Lloyd Paul ^a   Hata, Yasuaki ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; SOMATOMEDIN C; VASCULOTROPIN;

ARTICLE; BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENETIC TRANSCRIPTION; HUMAN; LASER COAGULATION; MOLECULAR BIOLOGY; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0032968550     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199904000-00011     Document Type: Article

References (112)

1. 1 Aiello LP, Gardner TW, King GL, Blankenship GW, Cavallerano J, Ferris F, et al.: Diabetic retinopathy: technical review. Diabetes Care 1998, 21:143-156. A comprehensive technical review of all clinical data concerning the natural history, epidemiology, clinical presentation, risks, treatment options, and therapeutic approaches to diabetic retinopathy. These data served as the foundation for the 1998 American Diabetes Association Position Statement on Diabetic Retinopathy.
2. 2 Ferris FL: How effective are treatments for diabetic retinopathy? JAMA 1993, 269:1290-1291.
3. 3 The Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991, 98:766-785.
4. 4 The Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. Int Ophthalmol Clin 1987, 27:265-272.
5. 5 Greene DA, Sima AA, Stevens MJ, Feldman EL, Killen PD, Henry DN, et al.: Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 1993, 9:189-217.
6. 6 Brownlee M: The pathological implications of protein glycation. Clin Invest Med 1995, 18:275-281.
7. 7 Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 1999, 48:1-9.
8. 8 Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
9. 9 Horton MA: The alpha v beta 3 integrin "vitronectin receptor". Int J Biochem Cell Biol 1997, 29:721-725.
10. 10 King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE: Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994, 45:179-188.
11. 11 Gartner S, Henkind P: Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol 1978, 22:291-312.
12. 12 Henkind P: Ocular neovascularization. The Krill memorial lecture. Am J Ophthalmol 1978, 85:287-301.
13. 13 Anonymous: Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986, 104:34-41.
14. 14 Aiello LM, Wand M, Liang G: Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology 1983, 90:814-820.
15. 15 Michaelson IC: The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948, 68:137-180.
16. 16 Ashton N : Retinal neovascularization in health and disease. Am J Ophthalmol 1957, 44:7-24.
17. 17 Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989, 58:575-606.
18. 18 Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, et al.: Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987, 84:2292-2296.
19. 19 Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, et al.: Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986, 233:545-548.
20. 20 Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66:1095-1104.
21. 21 McNeil PL, Muthukrishnan L, Warder E, D'Amore PA: Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989, 109:811-822.
22. 22 Gao H, Hollyfield JG: Basic fibroblast growth factor (bFGF) immunolocalization in the rodent outer retina demonstrated with an anti-rodent bFGF antibody. Brain Res 1992, 585:355-360.
23. 23 Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L: Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990, 108:869-872.
24. 24 Ozaki H, Okamoto N, Ortega S, Chang M, Ozaki K, Sadda S, et al.: Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization [see comments]. Am J Pathol 1998, 153:757-765. Targeted transgenic disruption of the bFGF gene in mice resulted in undetectable retinal bFGF levels but no reduction in ischemic retinal neovascularization. Conversely, overexpression of the bFGF gene driven by a rhodopsin promoter induced marked increases in photoreceptor bFGF expression without inducing retinal neovascularization or increasing retinal neovascularization under ischemic conditions. This is the most conclusive evidence to date that bFGF is neither necessary nor sufficient to induce retinal neovascularization.
25. 25 Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al.: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92:II365-II371.
26. 26 Goto F, Goto K, Weindel K, Folkman J: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels [see comments]. Lab Invest 1993, 69:508-517.
27. 27 Pepper MS, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189:824-831.
28. 28 LeRoith D, Roberts CT: Insulin-like growth factors. Ann NY Acad Sci 1993, 692:1-9.
29. 29 Poulsen J: Diabetes and anterior pituitary insufficiency. Final course and postmortem study of a diabetic patient with Sheehan's syndrome. Diabetes 1966, 15:73-77.
30. 30 Poulsen JE: The Houssay phenomenon in man. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953, 2:7-12.
31. 31 Sharp P, Fallon T, Brazier O, Sandler L, Joplin G, Kohner E: Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987, 30:199-207.
32. 32 Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, et al.: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-1709. Ischemic retinal neovascularization was inhibited in transgenic mice expressing a growth hormone (GH) antagonist gene and in normal mice given an inhibitor of GH secretion. Inhibition was inversely proportional to serum levels of GH and a downstream effector, IGF-I. Inhibition was reversed with exogenous IGF-I administration. GH inhibition did not diminish hypoxia-stimulated retinal VEGF or VEGF receptor expression. GH overexpression did not increase neovascularization. These data suggest that GH and IGF-1 are probably permissive factors for neovascularization and that systemic inhibition of GH or IGF-I, or both, may have therapeutic potential in preventing diabetic retinopathy.
33. 33 Averbukh E, Weiss O, Halpert M, Yanko R, Moshe R, Nephesh I, et al.: Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. Metabolism 1998, 47:1331-1336. Solution hybridization RNase protection assays demonstrated that hypoxia induced significant increases in retinal IGF-I receptor and IGF binding proteins 2 and 3; however, retinal IGF-I mRNA and serum GH was reduced.
34. 34 Grant MB, Guay C, Marsh R: Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res 1990, 9:323-335.
35. 35 Grant MB, Mames RN, Fitzgerald C, Ellis EA, Caballero S, Chegini N, et al.: Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. Ann NY Acad Sci 1993, 692:230-242.
36. 36 Dills DG, Moss SE, Klein R, Klein BE: Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes. Diabetes 1991, 40:1725-1730.
37. 37 Wang Q, Dills DG, Klein R, Klein BE, Moss SE: Does insulin-like growth factor 1 predict incidence and progression of diabetic retinopathy. Diabetes 1995, 44:161-164.
38. 38 Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
39. 39 Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
40. 40 Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
41. 41 Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev 1998, 17:241-248. An excellent review of the role of VEGF in tumor angiogenesis, which has numerous attributes similar to the neovascularization present in proliferate diabetic retinopathy.
42. 42 Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991, 47:211-218.
43. 43 Williams B: Vascular permeability/vascular endothelial growth factors: a potential role in the pathogenesis and treatment of vascular diseases. Vasc Med 1996, 1:251-258.
44. 44 Miller JW, Adamis AP, Aiello LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997, 13:37-50.
45. 45 Aiello LP: Clinical implications of vascular growth factors in proliferative retinopathies. Curr Opin Ophthalmol 1997, 8:19-31.
46. 46 Aiello LP: Vascular endothelial growth factor. 20th-century mechanisms, 21 st-century therapies. Invest Ophthalmol Vis Sci 1997, 38:1647-1652.
47. 47 Thieme H, Aiello LP, Takagi H, Ferrara N, King GL: Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1995, 44:98-103.
48. 48 Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Malecaze F, et al.: Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995, 164:385-394.
49. 49 Takagi H, King GL, Aiello LP: Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 1996, 45:1016-1023.
50. 50 Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, et al.: Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995, 270:28316-28324.
51. 51 De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991.
52. 52 Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, et al.: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
53. 53 Adamis AP, Shima DT, Yeo KT, Yeo TK, Brown LF, Berse B, et al.: Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993, 193:631-638.
54. 54 Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995, 113:1538-1544.
55. 55 Simorre-Pinatel V, Guerrin M, Chollet P, Penary M, Clamens S, Malecaze F, et al.: Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci 1994, 35:3393-3400.
56. 56 Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al.; Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994, 35:101-111.
57. 57 Dorey CK, Aouididi S, Reynaud X, Dvorak HF, Brown LF: Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat [see comments] [published erratum appears in Arch Ophthalmol 1997, 115:192]. Arch Ophthalmol 1996, 114:1210-1217.
58. 58 Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E: Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996, 37:290-299.
59. 59 Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S: Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res 1996, 15:175-184.
60. 60 Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995, 92:905-909.
61. 61 Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity [see comments] [published erratum appears in Arch Ophthalmol 1997 115:427]. Arch Ophthalmol 1996, 114:1219-1228.
62. 62 Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, et al.: Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994, 145:574-584.
63. 63 Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders [see comments]. N Engl J Med 1994, 331:1480-1487.
64. 64 Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al.: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450.
65. 65 Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M, et al.: Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 1997, 40:1107-1109. A study in 20 patients with diabetes (5 IDDM and 15 NIDDM) with proliferative diabetic retinopathy undergoing vitrectomy surgery and in 12 patients without diabetes evaluating serum and vitreous VEGF concentrations. Intravitreous concentrations of VEGF were markedly higher in diabetic compared to nondiabetic patients; however, differences in serum VEGF among the groups were not found.
66. 66 Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 1996, 80:241-245.
67. 67 Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, et al.: Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 1998, 212:410-414.
68. 68 Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al.: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995, 92:10457-10461.
69. 69 Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996, 114:66-71.
70. 70 Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996, 93:4851-4856.
71. 71 Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ, et al.: Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998, 39:180-188. Transgenic mouse data demonstrating that overexpression of VEGF by the photoreceptors is sufficient to produce retinal neovascularization. Retinal vessels grew toward the VEGF-producing photoreceptors, an inverted response compared with proliferative diabetic retinopathy.
72. 72 Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, et al.: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization [see comments]. Am J Pathol 1997, 151:281-291.
73. 73 Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H: Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995, 27:48-52.
74. 74 Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K: The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996, 74:819-825.
75. 75 Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, et al.: Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996, 103:1820-1828.
76. 76 Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480. Physiologic concentrations of intravitreal VEGF induced translocation of PKC α, β and δ and marked increases in retinal vascular permeability in rats that was comparable to that observed with direct PKC activation. A PKC β isoform-selective inhibitor abolished VEGF-induced retinal permeability when administered either intravitreally or orally.
77. 77 Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998, 47:1953-1959. One of the first demonstrations that VEGF action on retinal vascular permeability may be mediated through changes in the tight junction proteins. Diabetes induced a 35% reduction in occludin content in rats and VEGF reduced occluding content 54% in retinal endothelial cells.
78. 78 Kevil CG, Payne DK, Mire E, Alexander JS: Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 1998, 273:15099-15103. Studies demonstrating that VEGF can alter tight junction structure by reducing VE-cadherin and occludin content through an MAPK-dependent mechanism.
79. 79 Boulton M, Foreman O, Williams G, McLeod D: VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998, 82:561-568.
80. 80 Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW: Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997, 38:36-47.
81. 81 Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M: Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 1998, 152:1453-1462. An evaluation of retinas from nondiabetic eye donors and donors with 9 ± 5 SD years of diabetes and documented microangiopathy. The abundance and distribution of VEGF mRNA and protein were not altered in the diabetic retinas, possibly indicating that the diabetic environment is not sufficient to increase retinal VEGF expression. These results differ and suggest the opposite conclusion from similar earlier studies noted above.
82. 82 Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE: Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol 1997, 124:433-446. A study in rats demonstrating that physiologic concentrations of VEGF increased retinal blood flow consistent with increasing severity of diabetic retinopathy. Diabetic animals were also more sensitive to VEGF in this regard than were nondiabetic controls.
83. 83 Williams B, Gallacher B, Patel H, Orme C: Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997, 46:1497-1503. Studies demonstrating that high glucose concentrations can directly increase VEGF mRNA and peptide expression in human vascular smooth muscle cells through a PKC-dependent mechanism.
84. 84 Bontemps F, Vincent MF, Van den Berghe G: Mechanisms of elevation of adenosine levels in anoxic hepatocytes. Biochem J 1993, 290:671-677.
85. 85 Rego AC, Santos MS, Oliveira CR: Adenosine triphosphate degradation products after oxidative stress and metabolic dysfunction in cultured retinal cells. J Neurochem 1997, 69:1228-1235.
86. 86 Fischer S, Sharma HS, Karliczek GF, Schaper W: Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Brain Res Mol Brain Res 1995, 28:141-148.
87. 2 receptors may be more important than A1 for endothelial cell migration.
88. 88 Hashimoto E, Kage K, Ogita T, Nakaoka T, Matsuoka R, Kira Y: Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem Biophys Res Commun 1994, 204:318-324.
89. 89 Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP: Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci 1996, 37:2165-2176.
90. 90 Takagi H, King GL, Ferrara N, Aiello LP: Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 1996, 37:1311-1321.
91. 91 Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 1995, 92:11-14.
92. 92 Milanini J, Vinals F, Pouyssegur J, Pages G: p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998, 273:18165-18172.
93. 93 Pepper MS, Mandriota SJ: Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp Cell Res 1998, 241:414-425. These studies demonstrate that the synergistic interaction between VEGF and bFGF in the induction of angiogenesis in vitro may be mediated by bFGF's ability to increase VEGF receptor KDR mRNA and protein expression in nonocular endothelial cells. VEGF itself did not affect KDR expression.
94. 94 Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, et al.: Vascular endothelial growth factor induces tissue factor and matrix metalto-proteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998, 75:780-786.
95. 95 Mandriota SJ, Pepper MS: Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997, 110:2293-2302.
96. 96 Benezra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar-Shavit R: Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood 1993, 81:3324-3331.
97. 97 Saksela O, Rifkin DB: Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990, 110:767-775.
98. 98 Patterson C, Wu Y, Lee ME, DeVault JD, Runge MS, Haber E: Nuclear protein interactions with the human KDR/flk-1 promoter in vivo. Regulation of Sp1 binding is associated with cell type-specific expression. J Biol Chem 1997, 272:8410-8416. An excellent series of DNase I footprinting analysis experiments in human umbilical vein endothelial cells demonstrating that Sp1 interaction with the KDR promoter increases KDR gene expression and can account for cell-type expression specificity in vivo presumably because of chromatin structure.
99. 99 Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E: Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem 1995, 270:23111-23118.
100. 100 Hata Y, Duh E, Zhang K, Robinson GS, Aiello LP: Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol Chem 1998, 273:19294-19303. Extensive electrophoretic mobility shift assay analysis demonstrating that Sp1 and Sp3 bind to a novel recognition sequence in the KDR promoter region and that Sp1 induces KDR transcription but Sp3 attenuates this response. Additional data suggest that Sp1 is necessary for KDR promoter activity in endothelial cells and is sufficient to induce KDR expression in nonendothelial cells, thus possibly accounting for cell-type expression specificity.
101. 101 Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
102. 102 Chen LI, Nishinaka T, Kwan K, Kitabayashi I, Yokoyama K, Fu YH, et al.: The retinoblastoma gene product RB stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator. Mol Cell Biol 1994, 14:4380-4389.
103. 103 Lin SY, Black AR, Kostic D, Pajovic S, Hoover CN, Azizkhan JC: Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol 1995, 16:1668-1675.
104. 104 Guo D, Jia Q, Song HY, Warren RS, Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995, 270:6729-6733.
105. 105 Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt 1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269:26988-26995.
106. 106 Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, et al.: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996, 98:2018-2026.
107. 107 Mazure NM, Chen EY, Laderoute KR, Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997, 90:3322-3331.
108. 108 Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30336-30343.
109. 109 Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998, 39:171-179. Studies demonstrating that retinal neovascularization resulting from laser-induced retinal vein occlusion in pigs could be ameliorated by oral treatment with a PKC beta isoform selective inhibitor.
110. 110 Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor [see comments]. Science 1996, 272:728-731.
111. 111 Takagi H, King GL, Aiello LP: Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. Diabetes 1998, 47:1480-1488.
112. 112 Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994, 43:1122-1129.